Skip to main content
SpringerLink
Log in

Was kommt nach Docetaxel?

What comes after docetaxel?

  • Übersichten
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die Docetaxel-basierte Chemotherapie stellt derzeit den Standard in der Therapie des kastrationsresistenten Prostatakarzinoms dar. Im Progress nach primärer Chemotherapie steht jedoch keine Standardtherapie zur Verfügung. Therapieoptionen bestehen in der Wiederholung der Docetaxel-basierten Chemotherapie sowie in Kombinationen verschiedener Zytostatika. Darüber hinaus werden derzeit neue Antiandrogene wie Abirateron und MDV3100 in klinischen Studien untersucht, die v. a. auf die Hemmung der intratumoralen Testosteronsynthese abzielen. Der vorliegende Artikel enthält eine Übersicht über die verschiedenen Therapieansätze in klinischen Studien inklusive der Targeted-Therapien und zeigt Ansätze auf, die bereits jetzt im klinischen Alltag umgesetzt werden können.

Abstract

Chemotherapy with docetaxel represents the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC). In cases of progression after treatment with docetaxel no standard treatment recommendation exists since no treatment was able to show a survival benefit in clinical trials. This review focuses on available treatment options for patients with progressive CRPC and highlights promising treatments that are currently under investigation in clinical trials including abiraterone acetate and MDV3100.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  2. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25:3965–3970

    Article  PubMed  Google Scholar 

  3. Ansari J, Choo B, Hussain SA et al (2009) Docetaxel re-treatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pre-treated with docetaxel- An updated analysis. Genitourinary Cancers Symposium, Orlando, FL, p 185

  4. Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245

    Article  CAS  PubMed  Google Scholar 

  5. Berthold DR, Pond GR, de Wit R et al (2008) Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19:1749–1753

    Article  CAS  PubMed  Google Scholar 

  6. Sella A, Yarom N, Zisman A, Kovel S (2009) Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology 76:442–446

    Article  CAS  PubMed  Google Scholar 

  7. Loriot Y, Massard C, Gross-Goupil M et al (2009) Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 20:703–708

    Article  CAS  PubMed  Google Scholar 

  8. Mathew P, Dipaola R (2007) Taxane refractory prostate cancer. J Urol 178:36–41

    Article  Google Scholar 

  9. Petrylak D, Sartor AO, Witjey F et al (2009) Survival benefit in docetaxel-refractory androgen independent prostate cancer (AIPC) patients receiving second-line satraplatin in the SPARC trial. Genitourinary Cancers Symposium, Orlando, FL, p 163

  10. Morris MJ, Pandit-Taskar N, Stephenson RD et al (2009) Phase I/II study of docetaxel and 153Sm for castrate metastatic prostate cancer (CMPC): summary of dose-escalation dohorts and first report on the expansion cohort, 27nd edn. J Clin Oncol 27(15):5057

    Google Scholar 

  11. Attard G, Belldegrun AS, de Bono JS (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96:1241–1246

    Article  PubMed  Google Scholar 

  12. Reid AH, Attard G, Danila D et al (2009) A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J Clin Oncol 27(15):5047

    Google Scholar 

  13. Danila D, de Bono JS, Ryan CJ et al (2009) Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). J Clin Oncol 27(15):5048

    Google Scholar 

  14. Ryan CJ, Efstathiou E, Smith M et al (2009) Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 27(15):5046

    Google Scholar 

  15. Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–790

    Article  CAS  PubMed  Google Scholar 

  16. Scher HI, Beer TM, Higano C et al (2009) Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol 27(15:5011

    Article  Google Scholar 

  17. Moreira VM, Salvador JA, Vasaitis TS, Njar VC (2008) CYP17 inhibitors for prostate cancer treatment–an update. Curr Med Chem 15:868–899

    Article  CAS  PubMed  Google Scholar 

  18. Zhu YS, Imperato-McGinley JL (2009) 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci 1155:43–56

    Article  CAS  PubMed  Google Scholar 

  19. Eichenberger T, Trachtenberg J, Toor P, Keating A (1989) Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J Urol 141:190–191

    CAS  PubMed  Google Scholar 

  20. Maria MA, Morrissey C, O’Keane C et al (2006) Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer 106:2743–2752

    Article  Google Scholar 

  21. Arena F (2008) Dutasteride in the treatment of hormone refractory prostate cancer. Minerva Urol Nefrol 60:71–76

    CAS  PubMed  Google Scholar 

  22. Small EJ, Baron AD, Fippin L, Apodaca D (1997) Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157:1204–1207

    Article  CAS  PubMed  Google Scholar 

  23. Small EJ, Baron A, Bok R (1997) Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80:1755–1759

    Article  CAS  PubMed  Google Scholar 

  24. Taplin ME, Ko Y, Regan MM et al (2008) Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol 26(Suppl):5068

    Google Scholar 

  25. Periman PO, Sonpavde G, Bernold DM et al (2008) Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy. J Clin Oncol 26(Suppl):5157

    Google Scholar 

  26. Ohlmann CH, Markert E, Gerharz M et al (2008) Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer. Urologe A 47:1218–1223

    Article  PubMed  Google Scholar 

  27. Rosenberg JE, Weinberg VK, Kelly WK et al (2007) Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110:556–563

    Article  CAS  PubMed  Google Scholar 

  28. Ross RW, Beer TM, Jacobus S et al (2008) A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112:521–526

    Article  CAS  PubMed  Google Scholar 

  29. Canil CM, Moore MJ, Winquist E et al (2005) Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23:455–460

    Article  CAS  PubMed  Google Scholar 

  30. Gravis G, Bladou F, Salem N et al (2008) Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 1624–1628

  31. Lin AM, Rini BI, Weinberg V et al (2006) A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98:763–769

    Article  CAS  PubMed  Google Scholar 

  32. Rao K, Goodin S, Levitt MJ et al (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62:115–122

    Article  CAS  PubMed  Google Scholar 

  33. Steinbild S, Mross K, Frost A et al (2007) A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 97:1480–1485

    Article  CAS  PubMed  Google Scholar 

  34. de Bono JS, Bellmunt J, Attard G et al (2007) Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25:257–262

    Article  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben.

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstraße 1, 66421, Homburg/Saar, Deutschland

    C.-H. Ohlmann & M. Stöckle

Authors
  1. C.-H. Ohlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Stöckle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C.-H. Ohlmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohlmann, CH., Stöckle, M. Was kommt nach Docetaxel?. Urologe 49, 64–68 (2010). https://doi.org/10.1007/s00120-009-2146-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-009-2146-6

Schlüsselwörter

Keywords

Search

Navigation